公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma | Italiano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. | Cancer Immunology, Immunotherapy | 5 | 5 | |
2009 | Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors | CHIA-CHI LIN ; Calvo E.; Papadopoulos K.P.; Patnaik A.; Sarantopoulos J.; Mita A.C.; Preston G.G.; Mita M.M.; Rodon J.; Mays T.; Yeh I.-T.; O'Rourke P.; Takimoto C.H.; Dancey J.E.; Chen H.; Tolcher A.W. | Cancer Chemotherapy and Pharmacology | 15 | 13 | |
2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 |